Drugs that contain one or more fluorine atoms tend to be more stable, more powerful, and easier for the body to absorb. For those reasons, drug developers would like to be able to incorporate fluorine or a fluorine-containing unit known as trifluoromethyl into new experimental drugs, but this has been very difficult to do.
Now, a team of chemists at MIT and Boston College has discovered a new type of catalyst that can incorporate a trifluoromethyl group within a variety of organic molecules. The availability of these exceptionally efficient and selective catalysts should allow researchers to rapidly generate potential new fluorinated drugs, including antibiotics and anticancer agents, for testing.
